Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in New Jersey: - Cooper Hospital University Medical Center — Camden, New Jersey
- Jefferson Cherry Hill Hospital — Cherry Hill, New Jersey
- Trinitas Hospital and Comprehensive Cancer Center - Williamson Street Campus — Elizabeth, New Jersey
- Englewood Hospital and Medical Center — Englewood, New Jersey
- Hackensack University Medical Center — Hackensack, New Jersey
Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in New Jersey: - Jefferson Cherry Hill Hospital — Cherry Hill, New Jersey
- Englewood Hospital and Medical Center — Englewood, New Jersey
- Virtua Samson Cancer Center — Moorestown, New Jersey
- Morristown Medical Center — Morristown, New Jersey
- Riverview Medical Center/Booker Cancer Center — Red Bank, New Jersey
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achie…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05812807
Sites in New Jersey: - Cooper Hospital University Medical Center — Camden, New Jersey
- Jefferson Cherry Hill Hospital — Cherry Hill, New Jersey
- Trinitas Hospital and Comprehensive Cancer Center - Williamson Street Campus — Elizabeth, New Jersey
- Englewood Hospital and Medical Center — Englewood, New Jersey
- Hackensack University Medical Center — Hackensack, New Jersey
Phase 3 Recruiting Academic/Other
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…
Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth — Middletown, New Jersey
- Memorial Sloan Kettering Bergen — Montvale, New Jersey
- Virtua Samson Cancer Center — Moorestown, New Jersey
- Morristown Medical Center — Morristown, New Jersey
Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in New Jersey: - Morristown Medical Center — Morristown, New Jersey
- Newton Medical Center — Newton, New Jersey
- Robert Wood Johnson University Hospital Somerset — Somerville, New Jersey
- Overlook Hospital — Summit, New Jersey
- Holy Name Hospital — Teaneck, New Jersey
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in New Jersey: - Summit Medical Group — Berkeley Heights, New Jersey
- Ocean University Medical Center — Brick, New Jersey
- AtlantiCare Health Park-Cape May Court House — Cape May Court House, New Jersey
- AtlantiCare Surgery Center — Egg Harbor, New Jersey
- Hunterdon Medical Center — Flemington, New Jersey
Phase 3 Recruiting NIH
This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer ret…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07391774
Sites in New Jersey: - Jefferson Cherry Hill Hospital — Cherry Hill, New Jersey
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
- Sidney Kimmel Cancer Center Washington Township — Sewell, New Jersey
Phase 3 Recruiting Industry
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early b…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06492616
Sites in New Jersey: - MD Anderson Cancer Center at Cooper — Camden, New Jersey
- Summit Medical Group — Florham Park, New Jersey
- John Theurer Ctr-Hackensack UMC — Hackensack, New Jersey
- Rutgers Cancer Institute — New Brunswick, New Jersey
Phase 3 Recruiting Industry
The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor recept…
Sponsor: Eli Lilly and Company
NCT ID: NCT07174336
Sites in New Jersey: - Jefferson Health - Cherry Hill — Cherry Hill, New Jersey
- Sidney Kimmel Cancer Center - Washington Township — Sewell, New Jersey
- Atlantic Health System Overlook Medical Center — Summit, New Jersey
Phase 3 Recruiting Industry
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positi…
Sponsor: Pfizer
NCT ID: NCT07062965
Sites in New Jersey: - Hackensack University Medical Center — Hackensack, New Jersey
Phase 3 Recruiting Industry
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metasta…
Sponsor: BriaCell Therapeutics Corporation
NCT ID: NCT06072612
Sites in New Jersey: - Hunterdon Medical Center — Flemington, New Jersey
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in th…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06966700
Sites in New Jersey: - Hackensack Univ Medical Center (HUMC) ( Site 0007) — Hackensack, New Jersey
- Rutgers Cancer Institute of New Jersey ( Site 0076) — New Brunswick, New Jersey
Phase 3 Recruiting Industry
This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participant…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06790693
Sites in New Jersey: - Astera Cancer Care East Brunswick — East Brunswick, New Jersey
- Summit Medical Group — Florham Park, New Jersey
Phase 3 Recruiting Industry
This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutati…
Sponsor: Relay Therapeutics, Inc.
NCT ID: NCT06982521
Sites in New Jersey: - John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
- Rutgers Cancer Institute — New Brunswick, New Jersey
Phase 3 Recruiting Industry
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who ha…
Sponsor: LeonaBio
NCT ID: NCT05696626
Sites in New Jersey: - New Jersey Cancer Care, PA — Belleville, New Jersey
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Phase 1, Phase 2 Recruiting Industry
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…
Sponsor: Genmab
NCT ID: NCT05579366
Sites in New Jersey: - MD Anderson Cancer Center at Cooper- Two Cooper Plaza — Camden, New Jersey
Phase 2 Recruiting Academic/Other
The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the disease. Partic…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT06075953
Sites in New Jersey: - Englewood Hospital and Medical Center — Englewood, New Jersey
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06618287
Sites in New Jersey: - John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
Phase 2 Recruiting Academic/Other
The researchers are doing this study to find out if the study drug, enzalutamide, alone or combined with the study drug, mifepristone, is effective in treating advanced or metastatic androgen receptor-positive (AR+) triple negative breast …
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06099769
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
Phase 1, Phase 2 Recruiting Industry
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatmen…
Sponsor: Hoffmann-La Roche
NCT ID: NCT04802759
Sites in New Jersey: - Regional Cancer Care Associates LLC (RCCA) - Freehold Location — Freehold, New Jersey
- Regional Cancer Care Associates LLC ? Howell Division — Howell Township, New Jersey
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a fi…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in New Jersey: - John Theurer Cancer Center — Hackensack, New Jersey
Phase 2 Recruiting Academic/Other
The researchers are doing this study to find out whether the study drug, SDX-7320, when combined with the standard chemotherapy eribulin, is an effective treatment for people with TNBC and metabolic dysfunction. The researchers will also l…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT05570253
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge (All Protocol Activities) — Basking Ridge, New Jersey
- Hackensack Meridian Health — Hackensack, New Jersey
- Memorial Sloan Kettering Monmouth (All Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All Protocol Activities) — Montvale, New Jersey
Phase 2 Recruiting Academic/Other
Thie purpose of this study is to find out whether a personalized treatment approach-using a series of ctDNA tests along with standard imaging scans to help decide when to step up (escalate) or decrease (de-escalate) sequential treatments (…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07459673
Sites in New Jersey: - Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering at Monmouth (Limited Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering at Bergen (Limited Protocol Activities) — Montvale, New Jersey
Phase 1, Phase 2 Recruiting Academic/Other
This is a pilot study to evaluate the effects of azeliragon to decrease cardiac toxicity from chemotherapy and the safety of azelirgaon when given with chemotherapy. The Investigators hypothesize that there will be no significant interacti…
Sponsor: Georgetown University
NCT ID: NCT05256745
Sites in New Jersey: - John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
Phase 1 Recruiting Industry
This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients w…
Sponsor: Relay Therapeutics, Inc.
NCT ID: NCT05216432
Sites in New Jersey: - Rutgers University — New Brunswick, New Jersey